Rho-kinase inhibition in the therapy of cardiovascular disease

Cardiology in Review

Volumn 13, Issue 6, 2005, Pages 285-292

  Lai, Andrew ^a   Frishman, William H ^b,c  

^a KAISER PERMANENTE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Angina; Fasudil; Ischemia; Rho kinase

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; GUANOSINE TRIPHOSPHATASE; RHO KINASE; RHO KINASE INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CELL STRUCTURE; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY SPASM; ENZYME INHIBITION; FOCAL ADHESION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; NONHUMAN; REVIEW; SMOOTH MUSCLE CONTRACTION; STRESS FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 27644489210     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000138079.91392.37     Document Type: Review

References (41)

1. Madaule P, Axel R. A novel Ras-related gene family. Cell. 1985;41:31-40.
2. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol. 2001;11:471-477.
3. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signaling. Cell Signal. 1999;11:545-554.
4. Wettschureck N, Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med. 2002;80:629-638.
5. Leung T, Manser E, Tan L, et al. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem. 1995;270:29051-29054.
6. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J. 1996;15:2208-2216.
7. Feng J, Ito M, Kureishi Y, et al. Rho-associated kinase of chicken gizzard smooth muscle. J Biol Chem. 1999;274:3744-3752.
8. Gong MC, Kinter MT, Somlyo AV, et al. Arachidonic acid and diacylglycerol release associated with inhibition of myosin light chain dephosphorylation in rabbit smooth muscle. J Physiol (Lond). 1995; 486:113-122.
9. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996;271: 20246-20249.
10. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994;372:231-236.
11. Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin 11. J Physiol (Lond). 2000;522:177-185.
12. 11a. Noma K, Higashi Y, Jitsuiki D, et al. Smoking activates rho-kinase in smooth muscle cells of forearm vasculature in humans. Hypertension. 2003;41:1102-1105.
13. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho Family GTPase in mammalian cells. Ann Rev Biochem. 1999;68:459-486.
14. Ishizaki T, Uehata M, Tamechika I, et al. Pharmacological properties of Y-27632, a specific inhibitor of Rho-associated kinases. Mol Pharmacol. 2000;57:976-983.
15. Seto M, Sasaki Y, Hidaka H, et al. Effects of HA1077, a protein kinase inhibitor, on myosin phosphorylation and tension in smooth muscle. Eur J Pharmacol. 1991;195:267-272.
16. Ono-Saito N, Niki I, Hidaka H. H-series protein kinase inhibitors and potential clinical applications. Pharmacol Ther. 1999;82:123-131.
17. Satoh S, Utsunomiya T, Tsurui K, et al. Pharmacological profile of hydroxyfasudil as a selective Rho kinase inhibitor on ischemic brain damage. Life Sci. 2001;69:1441-1453.
18. Utsunomiya T, Satoh S, Ikegaki I, et al. Antianginal effects of hydroxyfasudil, a Rho-kinase inhibitor, in a canine model of effort angina. Br J Pharmacol. 2001;134:1724-1730.
19. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40:751-761.
20. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation. 2000;101:1319-1323.
21. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545-1547.
22. Kaski JC, Rosano G, Collins P. Cardiac syndrome X: clinical characteristics and left ventricular function: a long-term follow-up study. J Am Coll Cardiol. 1995;25:807-814.
23. Mohri M, Koyanagi M, Egashira K, et al. Angina pectoris caused by coronary microvascular spasm. Lancet. 1998;351:1165-1169.
24. Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003;41:15-19.
25. Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease (6th Edition): A Textbook of Cardiovascular Medicine. Philadelphia: WB Saunders; 2001:941-971.
26. 24a. Yada Y, Shimokawa H, Hiramatsu O, et al. Beneficial effect of hydroxyfasudil, a specific rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo. J Am Coll Cardiol. 2005;45:599-607.
27. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001; 15:1062-1064.
28. Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
29. Davies SP, Reddy H, Caivano M, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
30. Masumoto A, Hirooka Y, Shimokawa H, et al. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001;38:1307-1310.
31. Satoh S, Ueda Y, Koyanagi M, et al. Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. J Mol Cell Cardiol. 2003;35:59-70.
32. Little WC, Cheng CP, Eluelin L, et al. Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. Cardiovasc Drugs Ther. 1995:657-663.
33. Sellier P. Angina pectoris in patients with a history of myocardial infarction. Eur Heart J. 1996;17:25-29.
34. Noll G, Luscher TF. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade. Cardiology. 1998;89:10-15.
35. Browne RK, Dimmitt DC, Miller LD, et al. Relationship between plasma diltiazem and cardiovascular responses in conscious dogs. J Cardiovasc Pharmacol. 1983;5:483-490.
36. Skarvan K, Priebe HJ. Cardiovascular effects of diltiazem in the dog. Br J Anaesth. 1988;60:660-670.
37. 34a. Kishi T, Hirooka Y, Masumoto A, et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation. 2005;111:2741-2747.
38. Janjua N, Mayer SA. Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care. 2003;9:113-119.
39. Wang H, Eto M, Steers WD, et al. Rho A-mediated Ca2+ sensitization in erectile function. J Biol Chem. 2002;277:30614-30621.
40. Cavarape A, Endlich N, Assaloni R, et al. Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo. J Am Soc Nephrol. 2003;14:37-45.
41. Wang Y-X, Martin-McNulty B, da Cunha V, et al. Fasudil, a rho-kinase inhibitor, attenuates angiotensin 11-induced abdominal aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis. Circulation. 2005;111:2219-2226.